Transgene Biotek Limited has scheduled a Board of Directors meeting for Saturday, October 10, 2026, at 11:00 am. The primary agenda is to consider and approve the appointment of M/s. Eswara Rao & Co., Chartered Accountants, as the company's statutory auditors.

This appointment aims to fill a casual vacancy created by the resignation of the previous auditors, M/s. Vasavi & Co., Chartered Accountants. The proposed appointment is subject to the recommendation of the Audit Committee and subsequent approval by shareholders at a general meeting.

Auditor appointment details

The company received the consent letter, eligibility certificate, and other applicable confirmations from the proposed firm. The appointment will be executed in accordance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory compliance

The intimation was submitted to the stock exchange pursuant to Regulation 29 of the SEBI (LODR) Regulations, 2015. The Board will also consider such other matters as may be decided during the meeting. The company confirmed that all necessary regulatory documents have been received from the proposed audit firm.

Transgene announced that its management team will meet institutional investors during the Investor Access Event in Paris on October 6, 2026. The biotech firm will discuss progress on its myvac individualized neoantigen therapeutic vaccines (INTV) platform and virus-based candidates.

Organized by Investor Access, the event connects listed companies with professional investors through targeted, pre-arranged meetings. The 2026 program brings together more than 190 professional investors and 90 listed companies across its events.

Clinical Pipeline Focus

During the event, Transgene will highlight developments within its core clinical-stage programs. Key topics include the myvac platform assets:

• TG4050: Currently in development for head and neck cancer.
• TG4070: In Phase 1 clinical development for non-small cell lung cancer (NSCLC).

The company will also address other virus-based programs from its emerging pipeline. Transgene is a biotechnology company focused on designing and developing virus-based targeted immunotherapies and vaccines.

About Transgene

Transgene’s lead asset, TG4050, is the first INTV based on the myvac platform and has demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4070 introduces proprietary AI-driven neoantigen selection and scalable cell-line manufacturing capabilities.

Additional viral vector-based assets include BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. The company also conducts innovative discovery and preclinical work aimed at developing novel viral vector-based modalities.